Overview

Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis

Status:
Completed
Trial end date:
1999-12-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Assess the safety and efficacy of olsalazine, a dimer of 5-aminosalicylic acid, in men with ankylosing spondylitis unresponsive to nonsteroidal anti-inflammatory drugs and physiotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
National Center for Research Resources (NCRR)
Collaborator:
University of Rochester
Treatments:
Olsalazine